Analysis and Characterization of Trauma-Induced Coagulopathy

创伤性凝血病的分析和表征

基本信息

项目摘要

DESCRIPTION (provided by applicant): Uncontrolled hemorrhage is the major cause of death in adults exposed to severe trauma. Trauma induced coagulopathy (TIC) occurs after injury and shock, accompanied by a "storm" of inflammatory and coagulation events leading to incapacitation of the hemostatic process. TICs compromise the hemostatic system because of dysregulated processes occurring on a systemic basis in which proteolytic systems destroy essential coagulation components. Previous studies have identified activated protein C-mediated destruction of the cofactor factor Va and implicated systemic fibrinolytic activity in which unregulated proteolysis destroys fibrinogen and parts of the plasma coagulation system. These terminal events observed in phlebotomy blood of TIC patients are caused by in vivo processes involving the proteins, cells and cytokines in blood and vascular tissues and tissue damage material entering the blood. The causes and breadth of TICs are not understood. This TACTIC proposal provides a comprehensive evaluation of the contributions of plasma proteins, blood cells, the vascular endothelium, the blood vessel, and extravascular tissue to TIC, making use of a unique infrastructure that includes already-funded DoD sites involved in trauma trials and Systems Biology. A comprehensive team approach by leading investigators in coagulation and inflammation research addresses the problem using a composite of in vitro and in vivo approaches to identify candidates responsible for TICs. Early translation of laboratory results into useful technology will be enabled by a set of 5 TACTIC trauma centers. Simultaneous with these studies, interactions with clinical centers engaged in DoD clinical trials will be developed in which research personnel at each center will be responsible for point-of-care studies and processing of blood samples. Collection techniques will utilize inhibitory cocktails to block ex vivo, post phlebotomy artifacts. Blood/plasma samples will be shipped to a secure repository and analyzed utilizing new technology to identify the natural history of TIC events. Continuation of TACTIC research projects will be dependent upon their potential utility for diagnosis and selection of therapy for trauma patients. Although uncontrolled bleeding is the major cause of death in people with severe traumatic injuries, the reasons for this bleeding are not completely understood. We plan to comprehensively describe the causes of trauma-related clotting and bleeding, and propose methods to diagnose the different causes and ultimately therapeutic interventions to prevent morbidity and mortality in traumatic settings.
描述(申请人提供):失控出血是暴露在严重创伤中的成年人死亡的主要原因。创伤性凝血障碍(TIC)发生在损伤和休克后,伴随着炎症和凝血事件的“风暴”,导致止血过程丧失能力。TICS损害止血系统,因为在全身性的基础上发生的失调过程中,蛋白质分解系统破坏基本的凝血成分。以往的研究已经证实激活的蛋白C介导了辅因子Va的破坏,并涉及到全身纤溶活性,其中无调控的蛋白分解破坏了纤维蛋白原和部分血浆凝血系统。在TIC患者的静脉采血中观察到的这些终末事件是由血液和血管组织中的蛋白质、细胞和细胞因子以及组织损伤物质进入血液的体内过程引起的。抽搐的原因和广度尚不清楚。这一策略建议全面评估血浆蛋白、血细胞、血管内皮细胞、血管和血管外组织对TIC的贡献,利用独特的基础设施,其中包括参与创伤试验和系统生物学的已获得资金的国防部地点。由凝血和炎症研究领域的主要研究人员组成的一个全面的团队方法,使用体外和体内方法的组合来解决这个问题,以确定导致抽搐的候选人。早期将实验室结果转化为有用的技术将由一套5个战术创伤中心实现。在这些研究的同时,将发展与参与国防部临床试验的临床中心的互动,每个中心的研究人员将负责护理点研究和血液样本的处理。收集技术将利用抑制性鸡尾酒来阻止体外、静脉切开后的人工制品。血液/血浆样本将被运往安全的储存库,并利用新技术进行分析,以确定TIC事件的自然历史。TRACT研究项目的继续将取决于它们对创伤患者的诊断和治疗选择的潜在效用。虽然失控出血是严重创伤患者死亡的主要原因,但出血的原因尚不完全清楚。我们计划全面描述与创伤相关的凝血和出血的原因,并提出诊断不同原因的方法,并最终提出治疗干预措施,以防止创伤环境中的发病率和死亡率。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Charles T Esmon其他文献

Charles T Esmon的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Charles T Esmon', 18)}}的其他基金

Analysis and Characterization of Trauma-Induced Coagulopathy
创伤性凝血病的分析和表征
  • 批准号:
    8743252
  • 财政年份:
    2013
  • 资助金额:
    $ 456.96万
  • 项目类别:
Analysis and Characterization of Trauma-Induced Coagulopathy
创伤性凝血病的分析和表征
  • 批准号:
    8884641
  • 财政年份:
    2013
  • 资助金额:
    $ 456.96万
  • 项目类别:
Validation of extracellular histones as biomarker and therapeutic target in sepsi
细胞外组蛋白作为脓毒症生物标志物和治疗靶点的验证
  • 批准号:
    7838494
  • 财政年份:
    2009
  • 资助金额:
    $ 456.96万
  • 项目类别:
Validation of extracellular histones as biomarker and therapeutic target in sepsi
细胞外组蛋白作为脓毒症生物标志物和治疗靶点的验证
  • 批准号:
    7939849
  • 财政年份:
    2009
  • 资助金额:
    $ 456.96万
  • 项目类别:
COBRE: OK MED RES FOUND: ADMINISTRATIVE CORE
COBRE:确定医学研究成果:管理核心
  • 批准号:
    7382052
  • 财政年份:
    2006
  • 资助金额:
    $ 456.96万
  • 项目类别:
COBRE: OK MED RES FOUND: ADMINISTRATIVE CORE
COBRE:确定医学研究成果:管理核心
  • 批准号:
    7171282
  • 财政年份:
    2005
  • 资助金额:
    $ 456.96万
  • 项目类别:
ENDOTHELIAL CELL PROTEIN C RECEPTOR
内皮细胞蛋白 C 受体
  • 批准号:
    6866594
  • 财政年份:
    2004
  • 资助金额:
    $ 456.96万
  • 项目类别:
Post-Translational Modifications in Host Defense
宿主防御的翻译后修饰
  • 批准号:
    6799770
  • 财政年份:
    2003
  • 资助金额:
    $ 456.96万
  • 项目类别:
Roles of EPCR and PAR I in Acute Lung Injury
EPCR 和 PAR I 在急性肺损伤中的作用
  • 批准号:
    6820193
  • 财政年份:
    2003
  • 资助金额:
    $ 456.96万
  • 项目类别:
Post-Translational Modifications in Host Defense
宿主防御的翻译后修饰
  • 批准号:
    6912816
  • 财政年份:
    2003
  • 资助金额:
    $ 456.96万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Research Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Standard Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 456.96万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了